Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2025-12-24 @ 11:42 PM
NCT ID:
NCT02521051
Eligibility Criteria:
Inclusion Criteria:
* Histologically or cytologically confirmed advanced, non-squamous, non-small cell lung cancer.
* Molecular confirmation of an ALK rearrangement.
* Age ≥ 18 years old.
* Life expectancy \> 12 weeks.
* Performance status 0-2.
* Adequate hematologic function:
* Adequate renal function:
* An estimated Glomerular Filtration Rate (eGFR) of at least 45 mL/min/1.73 m2
* International normalized ration (INR)≤ 1.5
* Partial thromboplastin time (PTT) ≤1.5 x upper limit of normal (ULN)
* For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.
* Able and willing to provide written informed consent
* Phase II Only:
* Presence of at least one measurable central nervous system (CNS) target lesion (At least 5 mm in size)
* Lesions must be untreated or progressive according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after previous local therapy.
* Participants who are receiving corticosteroids must be on a stable or decreasing dose
* At least one measurable extra-CNS lesion based upon RECIST version 1.1.
Exclusion Criteria:
* Squamous cell histology or mixed, predominantly squamous adenosquamous carcinoma
* Previous history of haemoptysis
* Tumour infiltrating into large vessels or infiltrating into the proximal tracheobronchial network
* Unstable, symptomatic brain metastases.
* History of hemorrhagic CNS metastases
* History of intracranial hemorrhage (either by clinical history or neuroimaging)
* History of or genetic predisposition to a bleeding diathesis or coagulopathy
* Therapeutic anticoagulation
* Current or recent (within 10 days of first dose of bevacizumab) use of aspirin (\> 325 mg/day)
* Clinically significant heart disease (i.e., active), stroke or myocardial infarction within 6 months prior to enrolment, unstable angina pectoris, congestive heart failure of grade \> II according to the New York Heart Association (NYHA), or cardiac arrhythmia requiring specific treatment
* Arterial or venous thromboembolic events within 6 months of study enrollment.
* Poorly controlled arterial hypertension (systolic \> 150 mm Hg and/or diastolic \> 100 mm Hg)
* Invasive surgical intervention within 28 days prior to the start of treatment
* Minor surgical intervention, including placement of a permanent catheter within 24 hours prior to the first infusion of bevacizumab.
* Non-healing wound, active peptic ulcer or bone fracture.
* Previous history of abdominal fistula, tracheoesophageal fistula or other fistula with grade 4 severity, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to enrolment.
* Proteinuria at baseline.
* Previous anti-angiogenic treatment
* Patients previously treated with alectinib (Phase II only).
* Radical radiotherapy to the thorax with curative intent within 28 days
* Cytotoxic chemotherapy within 21 days prior to enrolment.
* Treatment with crizotinib within 7 days prior to enrolment. For all other ALK Tyrosine kinase inhibitors (TKIs), the washout period should be ≥5 half-lives prior to enrolment.
* Any GI disorder that may affect absorption of oral medications
* Alanine transaminase (ALT) or aspartate transaminase (AST) \> 3 × ULN (≥5 × ULN for patients with concurrent liver metastasis)
* Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
* Acute viral or active autoimmune, alcoholic, or other types of hepatitis
* National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g. radiotherapy) (excluding alopecia),
* History of organ transplant.
* Co-administration of anti-cancer therapies other than those administered in this study.
* QTc \> 470 ms or patients with symptomatic bradycardia.
* Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days
* Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment.
* History of hypersensitivity to any of the additives in the alectinib drug formulation
* Documented allergy or hypersensitivity to monoclonal antibodies (bevacizumab)
* History of drug-induced pneumonitis or hypersensitivity pneumonitis from prior ALK TKI therapy.
* Pregnant or lactating women.
* Known HIV positivity or AIDS-related illness.
* Any condition or illness that could compromise patient safety or interfere with the evaluation of the study drugs.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02521051
Study Brief:
Protocol Section:
NCT02521051